Molecular Imaging: Page 89

AI can detect metastatic bone lesions on scintigraphy

By Erik L. Ridley

An artificial intelligence (AI) algorithm can identify and characterize suspicious bone lesions on whole-body bone scintigraphy exams in cancer patients, according to research published online September 4 in BMC Medical Imaging.

September 12, 2021

Lantheus touts Pylarify PET agent results at AUA meeting

By AuntMinnie.com staff writers

Lantheus Medical Imaging is directing attention to research presented at the recent 2021 American Urological Association (AUA) virtual annual meeting involving its Pylarify PET radiopharmaceutical (piflufolastat F-18).

September 9, 2021

PET identifies early responders to liver cancer treatment

By Will Morton

PET imaging can predict how liver cancer patients are going to respond early after transarterial radioembolization, according to a study published online September 8 in the American Journal of Roentgenology.

September 9, 2021

NorthStar, Point Biopharma ink Ac-225 supply deal

By AuntMinnie.com staff writers

NorthStar Medical Radioisotopes and Point Biopharma Global have signed a supply agreement covering the development and commercialization of the medical radioisotope actinium-225 (Ac-225).

September 7, 2021

Telix, Kettering to research PSMA radiotracer

By AuntMinnie.com staff writers

Kettering Health and Telix Pharmaceuticals have signed a deal to study Telix's investigational prostate-specific membrane antigen (PSMA)-targeting radiopharmaceutical, illuccix.

September 7, 2021

PET tracer assesses response to new prostate cancer treatment

By Will Morton

PET imaging can identify whether or not patients respond to an investigational treatment for prostate cancer, according to a pilot study published in the September issue of the Journal of Nuclear Medicine.

September 7, 2021

Hermes, Isotopia sign deal on dosimetry

By AuntMinnie.com staff writers

Nuclear medicine software developer Hermes Medical Solutions has signed a collaboration with Isotopia Molecular Imaging to support clinical studies to demonstrate the positive effects of personalized dosimetry and modulated radiopharmaceutical therapy on patient outcomes.

September 6, 2021

PET/MRI better than MRI alone for detecting prostate cancer

By Will Morton

Functional imaging with PET/MRI is better than anatomic imaging alone for detecting prostate cancer in men who have a significantly higher chance of developing the disease, according to research published August 31 in Radiology.

September 3, 2021

Eckert & Ziegler to amend file for GalliaPharm PET tracer

By AuntMinnie.com staff writers

Eckert & Ziegler Radiopharma submitted an amendment to its drug master file to the U.S. Food and Drug Administration (FDA) for its GalliaPharm PET radiotracer.

September 2, 2021

Second-look PET/CT catches cancer spread

By Will Morton

Is a second PET/CT scan worth it before radiotherapy treatment? Swiss clinicians think so, especially when there are delays of more than four weeks after initial scans in patients with advanced head and neck squamous cell cancer, according to a study published August 29 in Clinical and Translational Radiation Oncology.

September 1, 2021

PET reveals triple threat behind Alzheimer's dementia

By Will Morton

PET imaging has shown for the first time how a triple threat of brain activity drives dementia in Alzheimer's disease patients -- and researchers created a visual map that lights up the culprit in action. Study details were published August 26 in Nature Medicine.

August 30, 2021

NorthStar wins $37M DOE award for Mo-99 production

By AuntMinnie.com staff writers

The U.S. Department of Energy (DOE) Nuclear Security Administration has bestowed a $37 million award to NorthStar Medical Radioisotopes for the production of molybdenum-99 (Mo-99).

August 29, 2021

Previous Page

Page 89 of 614

Next Page